Alkem Laboratories Achieves 14% Revenue Growth in Q2 FY27 with Expanded MedTech Portfolio
Company reports ₹45,520 million revenue; international sales grow 22.3%, EBITDA margin at 22.5%, and integrates Occlutech business
Alkem Laboratories Ltd. posted a 13.8% revenue increase to ₹45,520 million in Q2 FY27 driven by robust India and international sales growth. The company's EBITDA rose 11.3% year-on-year to ₹10,252 million, with strategic expansion into MedTech through Occlutech integration. Despite an 11.7% net profit decline, Alkem continues focus on core business growth, improving operations, and capital deployment in pharmaceuticals, biotech, and MedTech.
Alkem Laboratories Limited
Investor Presentation
Alkem Laboratories Ltd. reported a strong financial performance for the quarter ended September 30, 2026, with total revenue increasing by 13.8% year-over-year to ₹45,520 million, supported by healthy growth in both domestic and international sales and strategic expansion into MedTech.
Within Q2 FY27, India sales grew by 9.5% to ₹30,275 million, contributing 68% of total revenue, while international sales surged 22.3% to ₹14,540 million, including a 2.4% growth in US sales and a 58% increase in non-US markets including Occlutech.
The company’s EBITDA increased 11.3% to ₹10,252 million, resulting in an EBITDA margin of 22.5%. However, net profit declined by 11.7% to ₹6,753 million owing to factors not detailed in the filing. R&D expenses rose to ₹1,953 million, representing 4.3% of revenue, reflecting increased investment in innovation.
Operationally, Alkem outperformed the Indian Pharmaceutical Market in key therapy areas with chronic segment growth of 22.4%. The quarter also marked the integration of MedTech business Occlutech, contributing ₹1,331 million to sales, signaling strategic business diversification.
Facility inspections showed mostly positive regulatory status with ongoing remediation at the Daman formulation site and successful inspections at other key facilities, ensuring compliance continuity.
Highlights
- Total revenue reached ₹45,520 million, growing 13.8% YoY in Q2 FY27.
- India sales accounted for ₹30,275 million (+9.5% YoY), 68% of total revenue.
- International sales grew 22.3% YoY to ₹14,540 million, with US and non-US segments contributing.
- EBITDA rose 11.3% to ₹10,252 million; EBITDA margin stood at 22.5%.
- R&D spend increased to ₹1,953 million, or 4.3% of revenue, up from 3.3% last year.
- Net profit declined 11.7% YoY to ₹6,753 million for the quarter ending September 30, 2026.
Key Data Snapshot
What happened
- Alkem Laboratories posted a 13.8% year-on-year revenue increase to ₹45,520 million for Q2 FY27 ended September 30, 2026.
- International sales grew 22.3% driven by strong non-US growth and a 2.4% increase in US sales.
- The company expanded its MedTech segment by integrating Occlutech from Q2 FY27 onwards.
- Net profit decreased by 11.7% to ₹6,753 million despite higher revenues and EBITDA growth.
Key details
- India business contributed 68% to total sales for Q2 FY27, growing 9.5% year-on-year.
- Chronic therapy segment outperformed Indian Pharmaceutical Market with 22.4% growth versus 16%.
- Research & Development expenses increased to ₹1,953 million, representing 4.3% of total revenue.
- Regulatory facility inspections were mostly favorable with remediation in progress at the Daman site.
Operational performance
- Alkem outperformed the Indian Pharmaceutical Market in key therapies including vitamins and minerals, pain management, anti-diabetic, cardiac, urology, respiratory, neuro/CNS, and dermatology.
- The company maintained steady US business performance despite pricing pressure, supported by volume growth.
- Non-US international business grew 58%, with 28.6% growth excluding Occlutech acquisition.
Regulatory and governance context
- Facilities at Baddi, Taloja, Ankleshwar, Mandva, and California received positive inspection reports with issuance of EIRs or zero observations.
- Daman formulation facility received an Official Action Indicated (OAI) in August 2026; response submitted and remediation efforts underway.
Highlights
- Total revenue reached ₹45,520 million, growing 13.8% YoY in Q2 FY27.
- India sales accounted for ₹30,275 million (+9.5% YoY), 68% of total revenue.
- International sales grew 22.3% YoY to ₹14,540 million, with US and non-US segments contributing.
- EBITDA rose 11.3% to ₹10,252 million; EBITDA margin stood at 22.5%.
- R&D spend increased to ₹1,953 million, or 4.3% of revenue, up from 3.3% last year.
- Net profit declined 11.7% YoY to ₹6,753 million for the quarter ending September 30, 2026.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on Investor Presentation
View allLatest corporate announcements and market updates in Investor Presentation.
Lord's Mark Industries Conducts Investor Call on Business Progress, Shares Audio and Video Recordings Online
Lord's Mark Industries Limited held an investor conference call on 19th November 2026 to update stakeholders on the company’s business progress and operational developments. Following SEBI regulations, the company has made audio and video recordings of the call accessible on its website.
Read Full StoryUrban Company to Hold Virtual Analyst and Investor Meeting with Major Asset Managers on November 25, 2026
Urban Company Limited has arranged a virtual group meeting with key asset management firms on November 25, 2026, providing an opportunity for investor engagement without sharing unpublished price-sensitive information.
Read Full StoryTata Technologies Publishes Investor Day 2026 Presentations Detailing Strategic Growth Focus and Innovation
Tata Technologies Limited has made available video recordings of its Investor Day held on November 19, 2026. These presentations cover comprehensive insights into the company's strategic initiatives and operational priorities across key areas for growth and innovation.
Read Full Story